AR065778A1 - Formas de dosificacion de liberacion retardada/pulsatil de tiempo especifico - Google Patents

Formas de dosificacion de liberacion retardada/pulsatil de tiempo especifico

Info

Publication number
AR065778A1
AR065778A1 ARP080101092A ARP080101092A AR065778A1 AR 065778 A1 AR065778 A1 AR 065778A1 AR P080101092 A ARP080101092 A AR P080101092A AR P080101092 A ARP080101092 A AR P080101092A AR 065778 A1 AR065778 A1 AR 065778A1
Authority
AR
Argentina
Prior art keywords
starch
pharmaceutical composition
composition according
core
weight
Prior art date
Application number
ARP080101092A
Other languages
English (en)
Inventor
Matteo Cerea
Stefano De Luigi Bruschi
Andrea Gazzaniga
Maria Edvige Sangalli
Lucia Zema
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of AR065778A1 publication Critical patent/AR065778A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma de dosificacion de liberacion retardada/pulsátil de tiempo específico que comprende: un nucleo que comprende al menos un principio activo y al menos un agente desintegrante; una capa selladora que rodea el nucleo que consiste esencialmente en uno o más polímeros hidrosolubles o insolubles en agua independientes del pH; un recubrimiento exterior que consiste esencialmente en uno o más polímeros hidrofílicos independientes del pH; donde: el al menos un agente desintegrante está presente en cantidades de 1-20% en peso y el al menos un principio activo está presente en cantidades de 1-80% en peso, respecto al nucleo; la capa selladora representa 0,1-10% en peso, respecto al nucleo; el recubrimiento exterior representa 5-500% en peso, respecto al nucleo. Estos nucleos recubiertos tienen la capacidad de asegurar la liberacion inmediata del principio activo luego de un tiempo de latencia pre-definido, independientemente de variaciones fisiologicas del pH que se producen en el tracto gastrointestinal de los mamíferos. Reivindicacion 6: Una composicion farmacéutica de acuerdo con la reivindicacion 1, caracterizada en que al menos un polímero contenido en la capa selladora es diferente al menos un polímero contenido en el recubrimiento exterior. Reivindicacion 11: Una composicion farmacéutica de acuerdo con la reivindicacion 1, caracterizada en que al menos un agente desintegrante se selecciona de celulosa modificada, almidon natural, almidon directamente compresible, almidon modificado, derivados de almidon y polivinilpirrolidona reticulada. Reivindicacion 12: Una composicion farmacéutica de acuerdo con la reivindicacion 7, caracterizada en que dicha celulosa modifica es carboximetilcelulosa sodica reticulada; dicha polivinilpirrolidona reticulada es crospovidona; dicho almidon natural se selecciona de almidon de maíz y almidon de patata; dicho almidon directamente compresible es almidon 1500; dicho almidon modificado se selecciona de carboximetilalmidon y glicolato de almidon de sodio; dicho derivado de almidon se selecciona de amilosa, ácido algínico y alginato de sodio. Reivindicacion 15: Una composicion farmacéutica de acuerdo con la reivindicacion 1, caracterizada en que al menos un principio activo es Zaleplon. Reivindicacion 20: Una composicion farmacéutica de acuerdo con la reivindicacion 1, caracterizada en que dicho al menos un polímero hidrofílico del recubrimiento exterior se selecciona de alquilcelulosas y polietilenglicoles. Reivindicacion 21: Una composicion farmacéutica de acuerdo con la reivindicacion 20, caracterizada en que dicha alquilcelulosa se selecciona de hidroxipropilmetilcelulosa, hidroxipropilcelulosa, hidroxietilcelulosa, metilcelulosa, carboximetilcelulosa.
ARP080101092A 2007-03-15 2008-03-14 Formas de dosificacion de liberacion retardada/pulsatil de tiempo especifico AR065778A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07104213A EP1970056A1 (en) 2007-03-15 2007-03-15 Time-specific delayed/pulsatile release dosage forms

Publications (1)

Publication Number Publication Date
AR065778A1 true AR065778A1 (es) 2009-07-01

Family

ID=38063792

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101092A AR065778A1 (es) 2007-03-15 2008-03-14 Formas de dosificacion de liberacion retardada/pulsatil de tiempo especifico

Country Status (11)

Country Link
US (1) US20100028426A1 (es)
EP (2) EP1970056A1 (es)
JP (1) JP2010521437A (es)
KR (1) KR20090119986A (es)
CN (1) CN101636153A (es)
AR (1) AR065778A1 (es)
BR (1) BRPI0808801A2 (es)
CA (1) CA2679210A1 (es)
MX (1) MX2009009862A (es)
RU (1) RU2452472C2 (es)
WO (1) WO2008110577A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030958T2 (en) 2008-04-18 2017-06-28 Intec Pharma Ltd Gastro-active drug delivery to carbidopa / levodopa
WO2010064139A2 (en) 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
EP2375903A4 (en) * 2008-12-15 2012-09-19 Somnus Therapeutics Inc METHOD FOR TREATING SILENTNESS
CN103816130B (zh) * 2014-01-22 2016-01-20 悦康药业集团有限公司 一种盐酸二甲双胍缓释片
US11975104B2 (en) 2016-07-11 2024-05-07 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
ES2106818T3 (es) * 1991-10-30 1997-11-16 Glaxo Group Ltd Composicion multicapa que contiene antagonistas de histamina o secotina.
WO1993019741A1 (en) * 1992-03-31 1993-10-14 Benzon Pharma A/S A pharmaceutical formulation
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
ES2199857T3 (es) * 1999-08-26 2004-03-01 Neurocrine Biosciences, Inc. Composiciones sedantes-hipnoticas de liberacion controlada y metodos relacionados con ellas.
AU2001247887A1 (en) * 2000-04-19 2001-11-07 Eurand America Inc. Dual mechanism timed release dosage forms for low dose drugs
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
WO2003103637A2 (en) * 2002-01-10 2003-12-18 Ranbaxy Laboratories Limited Modified release, multiple unit drug delivery systems
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
WO2005041935A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
EP1817010A4 (en) * 2004-11-22 2009-06-17 Dexcel Pharma Technologies Ltd CONTROLLED ABSORPTION OF STATINS IN THE INTESTINE
CA2603105A1 (en) * 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
CN101111230B (zh) * 2005-03-29 2010-05-19 赢创罗姆有限责任公司 包含对活性成分具有调节释放作用的小丸的多颗粒药用形式
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system

Also Published As

Publication number Publication date
BRPI0808801A2 (pt) 2014-08-19
KR20090119986A (ko) 2009-11-23
JP2010521437A (ja) 2010-06-24
CN101636153A (zh) 2010-01-27
WO2008110577A1 (en) 2008-09-18
EP1970056A1 (en) 2008-09-17
MX2009009862A (es) 2009-12-14
RU2009138048A (ru) 2011-04-20
RU2452472C2 (ru) 2012-06-10
CA2679210A1 (en) 2008-09-18
US20100028426A1 (en) 2010-02-04
EP2120888A1 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
AR065778A1 (es) Formas de dosificacion de liberacion retardada/pulsatil de tiempo especifico
JP2011519967A5 (es)
JP2010529999A5 (es)
JP2017088610A (ja) ７−［４−（４−ベンゾ［ｂ］チオフェン−４−イル−ピペラジン−１−イル）ブトキシ］−１Ｈ−キノリン−２−オン又はその塩を含む錠剤
AR069031A1 (es) Composicion
AR017747A1 (es) Perlas farmaceuticas con recubrimiento entcrico, opcionalmente recubiertas con un anti-adherente dispuesto en el exterior de dicho recubrimiento entcrico, y un procedimiento para preparar dichas perlas farmaccuticas con recubrimiento entcrico
ES2294979T1 (es) Formulacion de levetiracetam de liberacion prolongada.
JP2012502015A5 (es)
JP2008503475A5 (es)
RU2012153207A (ru) Лекарственная форма для доставки лекарственного средства в толстую кишку
RU2006106464A (ru) Лекарственные формы с замедленным высвобождением зипразидона
JP2008536931A5 (es)
JP2009519343A5 (es)
CR10668A (es) Comprimidos pediatricos de capecitabina
RU2007137434A (ru) Таблетированный препарат с замедленным высвобождением для вертиго
JP2012506861A5 (es)
TW200502008A (en) Patches for mucosa of oral cavity containing fentanyl
JP2010521437A5 (es)
JP2013087119A5 (es)
RU2014115733A (ru) Новая соль и медицинское применение
AR071706A1 (es) Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
JP2009519313A5 (es)
MX2008010879A (es) Composiciones farmaceuticas de sodio de fluvastatina.
HRP20130225T1 (hr) Formulacija s odgođenim otpuštanjem koja sadrži 3-(2-dimetilaminometilcikloheksil) fenol
CY1118290T1 (el) Φαρμακευτικες συνθεσεις δραστικων ουσιων, των οποιων παρακαμπτεται δυσκολα η οδος χορηγησης για την οποια προοριζονται

Legal Events

Date Code Title Description
FB Suspension of granting procedure